Direct oral anticoagulants
215 results
1 - 100Direct oral anticoagulants
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
Increased bleeding with switch from warfarin to direct oral anticoagulant in frail elderly (FRAIL-AF)
Direct oral anticoagulants associated with better outcomes than warfarin in older patients with stroke and AF (PROSPER)
Direct oral anticoagulants versus warfarin among atrial fibrillation patients with chronic kidney disease
Direct oral anticoagulants (DOACs) plus clarithromycin associated with higher risk of bleed than DOACs plus azithromycin
Direct oral anticoagulants are noninferior to low-molecular-weight heparin to prevent recurrent VTE in adults with cancer
The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant
Early initiation of direct oral anticoagulants after acute stroke with atrial fibrillation is at least as good as later initiation
Direct oral anticoagulants versus vitamin K antangonists in non-valvular atrial fibrillation
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
Mitral regurgitation
Aortic stenosis
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Indications for and implementation of anticoagulant therapy in atrial fibrillation
Benefits/harms of novel oral anticoagulants similar in general population and the elderly
ACCP guidelines for antithrombotics in atrial fibrillation
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
No benefit to continuing perioperative oral anticoagulation for patients undergoing transcatheter aortic-valve implantation
Concomitant use of oral anticoagulants and SSRIs associated with increased risk of major bleeding
Antithrombotic agents in primary health care
Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions
Deep vein thrombosis
Oral anticoagulation for prolonging survival in patients with cancer
Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
Extended anticoagulation may be helpul for patients with unprovoked VTE or PE